<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Shape</title>
	<atom:link href="http://www.tapanray.in/tag/shape/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Shape of Future Pharma Operations – Emerging A Pragmatic Outlook?</title>
		<link>http://www.tapanray.in/shape-of-future-pharma-operations-emerging-a-pragmatic-outlook/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=shape-of-future-pharma-operations-emerging-a-pragmatic-outlook</link>
		<comments>http://www.tapanray.in/shape-of-future-pharma-operations-emerging-a-pragmatic-outlook/#comments</comments>
		<pubDate>Mon, 12 Apr 2021 00:00:35 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[communication]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[F2F]]></category>
		<category><![CDATA[future]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[hybrid]]></category>
		<category><![CDATA[in-person]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[MR]]></category>
		<category><![CDATA[multichannel]]></category>
		<category><![CDATA[omnichannel]]></category>
		<category><![CDATA[operations]]></category>
		<category><![CDATA[outlook]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[platform]]></category>
		<category><![CDATA[Pragmatic]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[role]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[Shape]]></category>
		<category><![CDATA[solution]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Therapeutics]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10468</guid>
		<description><![CDATA[Just as newer reports come almost every day on safety, efficacy, dosage interval or span of immunity of Covid vaccines, similar reports are also reaching us about the possible future shape of pharma sales and marketing operations. Some hardcore optimists, &#8230; <a href="http://www.tapanray.in/shape-of-future-pharma-operations-emerging-a-pragmatic-outlook/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/shape-of-future-pharma-operations-emerging-a-pragmatic-outlook/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Supreme Court Suspends New Drug Trials in India&#8230;Time to Shape Up?</title>
		<link>http://www.tapanray.in/supreme-court-suspends-new-drug-trials-in-india-time-to-shape-up/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=supreme-court-suspends-new-drug-trials-in-india-time-to-shape-up</link>
		<comments>http://www.tapanray.in/supreme-court-suspends-new-drug-trials-in-india-time-to-shape-up/#comments</comments>
		<pubDate>Mon, 14 Oct 2013 00:00:21 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[advisory]]></category>
		<category><![CDATA[AE]]></category>
		<category><![CDATA[biologics]]></category>
		<category><![CDATA[CAC]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[ceravix]]></category>
		<category><![CDATA[Chaudhury]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[compensation]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[CTs]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[deaths]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[DTAB]]></category>
		<category><![CDATA[expert]]></category>
		<category><![CDATA[exploitation]]></category>
		<category><![CDATA[gardasil]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[mechanisms]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[Ministry]]></category>
		<category><![CDATA[MNCs]]></category>
		<category><![CDATA[NCE]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[NME]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[PSC]]></category>
		<category><![CDATA[Ranjit]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulations]]></category>
		<category><![CDATA[Roy]]></category>
		<category><![CDATA[SAE]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[SC]]></category>
		<category><![CDATA[Shape]]></category>
		<category><![CDATA[standing Committee]]></category>
		<category><![CDATA[stops]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[systems]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[TRC]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[Up]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=3839</guid>
		<description><![CDATA[On September 30, 2013, with a damning stricture to the Drug Regulator, the Supreme Court, in response to a Public Interest Litigation (PIL) filed by the NGO Swasthya Adhikar Manch, stayed approvals for 162 applications for local Clinical Trials (CTs) of new &#8230; <a href="http://www.tapanray.in/supreme-court-suspends-new-drug-trials-in-india-time-to-shape-up/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/supreme-court-suspends-new-drug-trials-in-india-time-to-shape-up/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>First ever &#8216;Code of Pharma Marketing Practices&#8217; by the Government: A strong signal to &#8220;Shape Up&#8221;!</title>
		<link>http://www.tapanray.in/first-ever-code-of-pharma-marketing-practices-by-the-government-a-strong-signal-to-shape-up/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=first-ever-code-of-pharma-marketing-practices-by-the-government-a-strong-signal-to-shape-up</link>
		<comments>http://www.tapanray.in/first-ever-code-of-pharma-marketing-practices-by-the-government-a-strong-signal-to-shape-up/#comments</comments>
		<pubDate>Mon, 18 Jul 2011 00:00:34 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[by]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[ever]]></category>
		<category><![CDATA[First]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[of pharmaceuticals]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Shape]]></category>
		<category><![CDATA[signal]]></category>
		<category><![CDATA[Strong]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[Up]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=227</guid>
		<description><![CDATA[After a protracted debate on the alleged ‘unethical marketing practices’ by the pharmaceutical companies, in May 2011, the Department of Pharmaceuticals (DoP) came out with a draft ‘Uniform Code of Pharmaceutical Marketing Practices (UCMP)’ to address this issue squarely and &#8230; <a href="http://www.tapanray.in/first-ever-code-of-pharma-marketing-practices-by-the-government-a-strong-signal-to-shape-up/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/first-ever-code-of-pharma-marketing-practices-by-the-government-a-strong-signal-to-shape-up/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Abbott – Piramal deal: the way future is expected to shape up</title>
		<link>http://www.tapanray.in/abbott-piramal-deal-the-way-future-is-expected-to-shape-up/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=abbott-piramal-deal-the-way-future-is-expected-to-shape-up</link>
		<comments>http://www.tapanray.in/abbott-piramal-deal-the-way-future-is-expected-to-shape-up/#comments</comments>
		<pubDate>Mon, 31 May 2010 01:30:00 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[acquisition]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[deal]]></category>
		<category><![CDATA[expected]]></category>
		<category><![CDATA[future]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[M&A]]></category>
		<category><![CDATA[merger]]></category>
		<category><![CDATA[monopoly]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Piramal]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Shape]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[Up]]></category>
		<category><![CDATA[valuation]]></category>
		<category><![CDATA[way]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=421</guid>
		<description><![CDATA[In my view, these are still very early days for such acquisitions of large domestic Indian pharmaceutical companies by the Global Pharma majors to gain momentum in the country. However, there is no doubt that in the near future, we &#8230; <a href="http://www.tapanray.in/abbott-piramal-deal-the-way-future-is-expected-to-shape-up/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/abbott-piramal-deal-the-way-future-is-expected-to-shape-up/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
